Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis

Robert Murphy, Kirk M. Doerger, Mark A. Nathan, Val Lowe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Physiologic uptake of 2-[18F]-fluoro-2-deoxy-D- glucose (FDG) by bowel can confound positron emission tomography/computed tomography (PET/CT) assessment for abdominal pathology, particularly within the bowel itself. We wished to determine if oral administration of the antimotility agent, Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate; G.D. Searle and Company, a division of Pfizer), prior to PET/CT scanning would reduce physiologic uptake of FDG by the small bowel and colon (lower gastrointestinal [GI] tract). Procedures: Patients undergoing PET/CT scans for lymphoma were enrolled in a prospective, randomized, double-blinded study and received either 10 mL water (control group) or 10 mL Lomotil (experimental group) orally 30-60 min prior to scanning. Scans were reviewed independently by two blinded experienced readers and scored for the degree of FDG activity in the lower GI tract relative to liver activity. Results: The administration of Lomotil prior to PET/CT scanning did not reduce physiologic FDG activity in the small bowel and colon. In contrast, increased radiotracer uptake by the lower GI tract was observed in the Lomotil group compared to the control group. Conclusions: Pretreatment with Lomotil prior to PET/CT scanning confers no benefit toward the reduction of physiologic FDG uptake by the small bowel and colon.

Original languageEnglish (US)
Pages (from-to)114-117
Number of pages4
JournalMolecular Imaging and Biology
Volume11
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Deoxyglucose
Pelvis
Abdomen
Lower Gastrointestinal Tract
Colon
Diphenoxylate
Control Groups
Fluorodeoxyglucose F18
Atropine
Oral Administration
Lymphoma
atropine sulfate-diphenoxylate hydrochloride drug combination
Positron Emission Tomography Computed Tomography
Pathology
Water
Liver

Keywords

  • Diphenoxylate/atropine
  • Lomotil
  • PET
  • Positron emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. / Murphy, Robert; Doerger, Kirk M.; Nathan, Mark A.; Lowe, Val.

In: Molecular Imaging and Biology, Vol. 11, No. 2, 2009, p. 114-117.

Research output: Contribution to journalArticle

@article{8016adc90c4944d0aac1b24f71f2e3fe,
title = "Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis",
abstract = "Purpose: Physiologic uptake of 2-[18F]-fluoro-2-deoxy-D- glucose (FDG) by bowel can confound positron emission tomography/computed tomography (PET/CT) assessment for abdominal pathology, particularly within the bowel itself. We wished to determine if oral administration of the antimotility agent, Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate; G.D. Searle and Company, a division of Pfizer), prior to PET/CT scanning would reduce physiologic uptake of FDG by the small bowel and colon (lower gastrointestinal [GI] tract). Procedures: Patients undergoing PET/CT scans for lymphoma were enrolled in a prospective, randomized, double-blinded study and received either 10 mL water (control group) or 10 mL Lomotil (experimental group) orally 30-60 min prior to scanning. Scans were reviewed independently by two blinded experienced readers and scored for the degree of FDG activity in the lower GI tract relative to liver activity. Results: The administration of Lomotil prior to PET/CT scanning did not reduce physiologic FDG activity in the small bowel and colon. In contrast, increased radiotracer uptake by the lower GI tract was observed in the Lomotil group compared to the control group. Conclusions: Pretreatment with Lomotil prior to PET/CT scanning confers no benefit toward the reduction of physiologic FDG uptake by the small bowel and colon.",
keywords = "Diphenoxylate/atropine, Lomotil, PET, Positron emission tomography",
author = "Robert Murphy and Doerger, {Kirk M.} and Nathan, {Mark A.} and Val Lowe",
year = "2009",
doi = "10.1007/s11307-008-0178-8",
language = "English (US)",
volume = "11",
pages = "114--117",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis

AU - Murphy, Robert

AU - Doerger, Kirk M.

AU - Nathan, Mark A.

AU - Lowe, Val

PY - 2009

Y1 - 2009

N2 - Purpose: Physiologic uptake of 2-[18F]-fluoro-2-deoxy-D- glucose (FDG) by bowel can confound positron emission tomography/computed tomography (PET/CT) assessment for abdominal pathology, particularly within the bowel itself. We wished to determine if oral administration of the antimotility agent, Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate; G.D. Searle and Company, a division of Pfizer), prior to PET/CT scanning would reduce physiologic uptake of FDG by the small bowel and colon (lower gastrointestinal [GI] tract). Procedures: Patients undergoing PET/CT scans for lymphoma were enrolled in a prospective, randomized, double-blinded study and received either 10 mL water (control group) or 10 mL Lomotil (experimental group) orally 30-60 min prior to scanning. Scans were reviewed independently by two blinded experienced readers and scored for the degree of FDG activity in the lower GI tract relative to liver activity. Results: The administration of Lomotil prior to PET/CT scanning did not reduce physiologic FDG activity in the small bowel and colon. In contrast, increased radiotracer uptake by the lower GI tract was observed in the Lomotil group compared to the control group. Conclusions: Pretreatment with Lomotil prior to PET/CT scanning confers no benefit toward the reduction of physiologic FDG uptake by the small bowel and colon.

AB - Purpose: Physiologic uptake of 2-[18F]-fluoro-2-deoxy-D- glucose (FDG) by bowel can confound positron emission tomography/computed tomography (PET/CT) assessment for abdominal pathology, particularly within the bowel itself. We wished to determine if oral administration of the antimotility agent, Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate; G.D. Searle and Company, a division of Pfizer), prior to PET/CT scanning would reduce physiologic uptake of FDG by the small bowel and colon (lower gastrointestinal [GI] tract). Procedures: Patients undergoing PET/CT scans for lymphoma were enrolled in a prospective, randomized, double-blinded study and received either 10 mL water (control group) or 10 mL Lomotil (experimental group) orally 30-60 min prior to scanning. Scans were reviewed independently by two blinded experienced readers and scored for the degree of FDG activity in the lower GI tract relative to liver activity. Results: The administration of Lomotil prior to PET/CT scanning did not reduce physiologic FDG activity in the small bowel and colon. In contrast, increased radiotracer uptake by the lower GI tract was observed in the Lomotil group compared to the control group. Conclusions: Pretreatment with Lomotil prior to PET/CT scanning confers no benefit toward the reduction of physiologic FDG uptake by the small bowel and colon.

KW - Diphenoxylate/atropine

KW - Lomotil

KW - PET

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=60049089370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049089370&partnerID=8YFLogxK

U2 - 10.1007/s11307-008-0178-8

DO - 10.1007/s11307-008-0178-8

M3 - Article

VL - 11

SP - 114

EP - 117

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 2

ER -